Highlights and Quick Summary
- Depreciation & Amortization Growth for the quarter ending June 29, 2021 was 70.13% (a -239.7% decrease compared to previous quarter)
- Year-over-year quarterly Depreciation & Amortization Growth decreased by -251.34%
- Annual Depreciation & Amortization Growth for 2020 was 3937.5%
- Twelve month Depreciation & Amortization Growth ending June 29, 2021 was -32.23% (a -20.85% decrease compared to previous quarter)
Trailing Depreciation & Amortization Growth for the last four month:
|29 Jun '21||30 Mar '21||30 Dec '20||—|
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Depreciation & Amortization Growth of Phathom Pharmaceuticals, Inc.Most recent Depreciation & Amortization Growthof PHAT including historical data for past 10 years.
Interactive Chart of Depreciation & Amortization Growth of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.